Innovative Industrial Properties, Inc. (IIPR) Earnings Call Transcript & Summary
May 5, 2026
What were the key takeaways from Innovative Industrial Properties, Inc.'s May 5, 2026 earnings call?
In the first quarter of 2026, Innovative Industrial Properties, Inc. (IIPR) reported total revenues of $69 million, reflecting a 3.5% increase from the previous quarter, driven by payments from PharmaCann. Adjusted Funds from Operations (AFFO) remained stable at $53.4 million or $1.88 per share, consistent with the prior quarter. Management highlighted significant regulatory progress with the rescheduling of cannabis to Schedule III, which is expected to enhance operator economics and stimulate growth opportunities, although no changes to guidance were provided for the fiscal year.
What topics did Innovative Industrial Properties, Inc. cover?
- Regulatory Developments: Management emphasized the significance of the DOJ's decision to move FDA-approved cannabis products to Schedule III, stating it is 'the most significant development affecting our business since our founding in 2016.' This change is expected to eliminate the burden of 280E for qualifying medical operators, enhancing their financial flexibility.
- Leasing Activity: IIPR signed new leases totaling approximately 331,000 square feet across four properties, indicating strong demand for their facilities. Management noted, 'We have now executed leases for the former Gold Flora assets' and are making progress on retenanting other properties.
- Capital Raising Efforts: The company raised $128 million in gross proceeds year-to-date and is pursuing additional financing totaling nearly $130 million. Management stated, 'We are encouraged by the level of interest from multiple new lenders,' indicating strong market confidence.
- Portfolio Stabilization: Management reported progress in stabilizing the portfolio, addressing tenant defaults, and executing leases for previously troubled assets. They noted, 'We've now addressed well north of 90% of those assets through LOIs, executed leases and lease discussions.'
- Life Science Investments: IIPR continues to invest in the life sciences sector, having funded $175 million of a $270 million commitment to IQHQ. Management believes this investment will be 'very accretive,' with expected returns exceeding 14%.
What were Innovative Industrial Properties, Inc.'s May 5, 2026 results?
- Total Revenue: $69 million (vs $66.7 million est, +3.5% QoQ)
- AFFO: $53.4 million (or $1.88 per share, inline with prior quarter)
- Debt Service Coverage Ratio: 11x (remains strong, indicating financial health)
- Liquidity: $177 million (consisting of $89 million cash and $87.5 million available under credit facilities)
- Capital Raised Year-to-Date: $128 million (includes $72 million preferred equity, $36 million common equity, $20 million secured debt)
- Total Commitment to IQHQ: $270 million (with $175 million funded to date)
The developments in regulatory changes and leasing activity position IIPR favorably for future growth. The strong capital raising efforts and focus on portfolio stabilization further enhance the investment thesis. Investors should monitor the execution of new leases and the impact of regulatory changes on tenant performance as potential catalysts for stock movement.
Earnings Call Speaker Segments
We appreciate you being on this call. With us today are Alan Gold, our Executive Chairman; Paul Smithers, President and Chief Executive Officer; David Smith, Chief Financial Officer; and Ben Regin, Chief Investment Officer. Prior to getting started, I want to remind all of you that certain statements we make on today's conference call — among them statements about our capital raising activities and about possible lease transactions that are governed by letters of intent — constitute forward-looking statements under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, and they carry risks and uncertainties. Results in reality could differ materially, and for a complete discussion of the risk factors that might cause actual results to diverge materially from what those forward-looking statements contain, we point you to our SEC filings, in particular our latest reports on Forms 10-K and 10-Q; we have no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, unless the law requires it. Also, during today's call, we will talk about certain non-GAAP financial information, including FFO, normalized FFO, and AFFO. That information, along with reconciliations to the most directly comparable GAAP financial measure, can be located in the earnings release we issued yesterday and in our 8-K filed with the SEC. I'll turn things over now to Alan. Alan?
Thank you, Eli. Good morning to all of you, and I appreciate you being with us for our earnings call covering the first quarter of 2026. To begin, I want to discuss cannabis being moved from Schedule 1 to 3 — a major regulatory shift that affects the cannabis sector. From where we stand, the administration's recent move regarding the medical cannabis market is a key milestone for this industry and an obvious indicator that progress at the federal level keeps happening. Even though it hasn't yet been expanded to cover the wider adult-use market, it strengthens the momentum toward a sensible regulatory framework. With that as the setting, the first quarter was a solid beginning to the year, and our team stayed committed to executing with discipline throughout the business. Persistent inflation, high interest rates and broader macroeconomic pressures keep making the operating environment difficult, yet our team has put in relentless effort to refine our portfolio, deploy capital wisely and keep our balance sheet both strong and flexible. Now, we've been busy on the debt and equity capital raising side, bringing in $128 million of gross proceeds so far this year. Beyond that, we are pursuing multiple secured and unsecured financing transactions that haven't closed yet, amounting to almost $130 million, among them a $56.5 million financing at an 8.75% rate that we anticipate being funded today. Should these financings be completed, we intend to apply the net proceeds toward handling our unsecured bond maturity this month and to supply extra capital that supports future growth and the execution of our strategic priorities. This method mirrors our ongoing emphasis on disciplined capital management and keeping balance sheet flexibility intact. Regarding the quarter, total revenues came to $69 million and AFFO reached $53.4 million, or $1.88 per share, matching what we reported last quarter. On the operational side, we achieved meaningful progress throughout our portfolio as we keep carrying out our leasing strategy. In the quarter, we executed new leases at 4 properties spanning roughly 331,000 square feet, which highlights the momentum we are generating across the portfolio and the demand for our high-quality mission-critical facilities. Moving to IQHQ; we still see this investment as a compelling strategic opportunity and a significant extension of our platform. So far, we have funded $175 million out of our $270 million commitment and remain confident that our entry point and the timing of this investment will look attractive over the long term. At the same time, we stay focused on executing throughout the business, driving performance in our current portfolio, chasing appealing opportunities in cannabis and directing capital toward where we find the strongest risk-adjusted returns. With a diversified platform that spans cannabis and life science, a strong balance sheet that has demonstrated access to capital and a management team with deep experience, we believe we are well positioned to build on our momentum and progress to deliver long-term value for our shareholders. With that, I'll hand the call over to Paul.
Appreciate that, Alan. During the prior month, the Department of Justice along with the acting Attorney General put out a final order that reclassifies FDA-approved cannabis goods — plus cannabis grown by state-licensed medical operators — into Schedule III. That's a landmark moment, and from where we sit, it's the single most consequential event to touch our company since we started up back in 2016. What this does is remove the 280E weight for medical operators who qualify, could open the door to tax relief applied retroactively, and sets up a faster DEA registration pathway for those medical operators. Equally significant, the DEA has relaunched the wider hearing process concerning whether marijuana as a category ought to be shifted into Schedule III, with that hearing scheduled to kick off on June 29 under a compressed timeline. When you put all of this together, we see these moves as a big leap ahead for the sector and a strong catalyst for better operator economics, broader access to capital, and a more supportive climate for growth and investment over the long haul. Turning to the state level, we're keeping an eye on how existing medical programs are expanding, especially in Texas; back in April, the Texas Compassionate Use Program handed conditional licenses to two of our tenant partners, Green Thumb Industries and Cresco Labs, which puts them alongside Texas Original, Trulieve, Verano and other players in that market. This kind of progress encourages us, and we're eager to see the program keep growing and the opportunities that generates for our tenants. On the subject of our present portfolio, as we pointed out in our March press release, we settled with PharmaCann on every piece of outstanding litigation tied to its lease defaults, and we're hard at work re-tenanting the properties that come back to us later this month. Throughout the portfolio, we've now signed leases covering the former Gold Flora assets, achieved meaningful headway on the former PharmaCann assets, and struck tentative deals with prospective new tenants for each of the 4 former 4Front properties, contingent on diligence and licensing sign-offs. I'd like to express gratitude to our team and everyone involved for the effort they've poured into steering us through these difficulties. Thanks to the steps we've taken, we're in a stronger position to push portfolio performance ahead from here. Having said that, I'll hand things over to Ben, who will walk through more specifics on our leasing activity and cover our other investment activities.
Appreciate that, Paul. So far this year, we've signed new leases adding up to 389,000 square feet spanning 5 properties in California, Illinois and Ohio, and we closed on the sale of a dispensary in Arizona. Like Paul said, we're happy with how things are going when it comes to stabilizing our portfolio and bringing Revolution into the assets formerly held by 4Front, PharmaCann and Gold Flora. Every one of the 3 former Gold Flora properties — 330,000 square feet in total — is now under lease; we signed lease agreements for our 70,000 square foot Palm Springs property in November 2025, our 204,000 square foot Desert Hot Springs property in January 2026, and our 56,000 square foot Palm Springs property in March 2026. On the 4Front side, tentative deals are in place with prospective new tenants covering all 4 properties, roughly 488,000 square feet spread across Illinois, Washington and Massachusetts. Those tentative deals are still contingent on customary diligence and licensing approvals, and we expect them to become effective once the receivership proceedings wrap up, which we currently anticipate later this year. When it comes to the former PharmaCann assets, in March we signed a lease for our 66,000 square foot property in Dwight, Illinois with Grown Rogue, a publicly traded multistate operator who is new to our tenant roster. In April, we signed a lease for our 58,000 square foot property in Ohio with Curaleaf, a public multistate operator and a tenant partner we've worked with for a long time. Beyond those executed leases, we signed a nonbinding LOI covering our 234,000 square foot facility in New York and are in the middle of lease negotiations subject to customary due diligence, including licensing and regulatory approvals; we're also still working through diligence and negotiating with a prospective tenant for our 71,000 square foot property in North Adams, Massachusetts. As for our 270,000 square foot property in Pennsylvania that was leased to the cannabis company as of quarter end, we took possession back on April 15 and are actively talking with a potential new tenant. There's no guarantee that any of these talks or negotiations will lead to a definitive lease being signed, but the demand we're seeing for our assets has us very pleased. Our 157,000 square foot property in Columbus, Ohio is still leased to Battle Green, which defaulted on its lease obligations in March. We're actively enforcing our rights under the lease, which includes starting eviction proceedings and pursuing the remedies available to us under applicable guarantees. Shifting to our life science portfolio. We've funded $175 million of our $270 million IQHQ commitment so far, with the remaining $95 million expected to be funded over time. As we move through 2026, the broader life science real estate market keeps showing signs of stabilization and improving momentum. Recent reports from CBRE and Colliers point to demand holding near pre-pandemic levels, while stronger equity performance and venture funding are supporting a more constructive backdrop for growth. Meanwhile, the market continues to digest the surplus of empty space left over from the earlier surge of new construction, yet fresh building activity has dropped considerably and what's in the works sits at lows rarely seen historically, a situation that ought to help bring supply and demand into better alignment down the road. Beyond that, we keep observing encouraging demand catalysts over the long haul in fields such as manufacturing, onshoring and research powered by AI, and in our view these will set the sector up for ongoing gains as time passes. Having said that, I'll now hand things over to David.
Thanks, Ben. Before I get into the quarter's numbers, I'd like to start with the bond maturity coming due this month, which, as we've noted on earlier calls, has been a central concern for us. Both during and after the close of the quarter, we've completed a set of capital-raising moves aimed at handling that maturity. So far this year, we've brought in $128 million in gross capital, made up of $72 million in preferred equity, $36 million in common equity, and $20 million in secured debt via a 3-year secured term loan carrying a fixed rate of 9% that we closed on not long ago. As Alan noted, we're also in the process of pursuing several secured and unsecured financing deals amounting to close to $130 million, among them a $56.5 million financing we anticipate will be funded today. Given the terms we're currently negotiating, those financings would come with an appealing blended rate of slightly above 8%; we're heartened by how much interest we're seeing from a number of new lenders and by the chance to obtain favorably priced capital to handle this maturity and supply extra capital supporting future growth. These possible financings are still contingent on various conditions, and we can give no assurance they'll close on the terms presently envisioned, or close at all. Now on to our results. In the first quarter, total revenues came to $69 million, up 3.5% from the fourth quarter; the main driver of that gain was payments we received from PharmaCann amounting to $3.2 million. Also, as we've previously disclosed, during the first quarter we collected $1.5 million in settlement of all remaining unpaid administrative rents owed from the Gold Flora receivership. Adjusted funds from operations, or AFFO, came to $53.4 million for the quarter, or $1.88 per share, matching what we posted in the fourth quarter of 2025. Now to the balance sheet. At March 31, total liquidity stood at roughly $177 million, split between $89 million of cash on hand and $87.5 million of availability under our revolving credit facilities. Our balance sheet credit metrics were once again outstanding this quarter, with a debt service coverage ratio above 11x and net debt to adjusted EBITDA at 1.1x; and thanks to our recent capital-raising activity, we keep very strong credit metrics, with a balance sheet set up for growth in 2026; with that, operator, please open the call for questions.
Ben, let me begin with you. Assuming my calculations are correct, I believe there are 8 leases you've executed that haven't started yet; combined with the deals for the 4Front properties, that number might reach 12 locations. I realize every transaction differs and you don't have full control over when each one begins. That said, could those 12 leases be grouped according to how many you anticipate contributing during 2026 as opposed to 2027 or perhaps later?
Tom, the way I'd frame it, I suppose, is that in a normal deal, following lease signing, there's typically a regulatory approval step and a license transfer. Then, after the lease becomes effective, a free rent period may apply. We've observed that averaging anywhere between 3 months and 12 to 18 months at the extreme. I appreciate you bringing up the leasing activity. The demand we keep seeing throughout the portfolio has made us quite happy. Regarding some of the earlier tenant problems — PharmaCann, 4Fronts, Gold Flora — we have by now handled considerably more than 90% of those assets via LOIs, signed leases, and lease negotiations currently underway. I'd also mention, as we consider the modeling, a free rent period may exist, and a license transfer period may exist. However, the triple net expenses generally get shifted to the tenants once the lease is executed. That represents an additional boost to our earnings.
Then, if I recall correctly from the previous quarter, you noted — and as I already said, every deal differs — that there was a spread in how those rents came out when executed. The specific figures escape me, but you provided a span running from essentially flat all the way to a 50% decline in certain instances. Regarding the ones you closed during this quarter, where did they land relative to earlier rents?
That framing still holds up, in my view. I'd say that same spread is true across the board. Another thing worth remembering is how little capital we've had to put in, and that's been consistent everywhere. What I mean is, typically, we're talking about $5 to $10 per foot, and occasionally these are as-is transactions — something I'd call quite unusual for the real estate sector, being able to bring in new tenants for these properties, and the sheer amount of leasing we've gotten done has come at a truly negligible expense on our end.
Understood. Understood. Then this next one may sound somewhat out there right now. Yet we've noticed a rise in M&A activity spreading through the cannabis sector, in its early stages. But take, for instance, what's going on with cannabis where — they said your tenant Holistic is taking over operations in Ohio. As more resolutions and workouts like that appear, could IIPR step in and supply the next wave of operators with capital for assets that were previously owner-occupied? Or is that thinking too far ahead?
No. I don't believe we're thinking too far ahead, or that anyone else is. I think that — with the first phase of the rescheduling, and I realize much more remains on that front, we are seeing our tenants generally get stronger across the industry; and I think we're also seeing greater interest in the industry and possible growth opportunities within cannabis. Whether that's 6 months, 12 months, or 36 months away, it's a story that keeps evolving.
Understood. Then one final item from me, Paul, regarding the rescheduling. You referenced the administrative hearings on June 29 getting underway once more. What we're trying to figure out is that clearly there is legalization on the medical cannabis side through the DOJ's final order. It appears possible that those administrative hearings could broaden that order; and obviously it's too soon to say, but how likely is it that we could wind up with something like a divided result, where medical gets an exemption from 280E, yet adult use continues to face tougher taxation.
Right, Tom, that strikes me as a reasonable question. Over the near term — and by near term I mean the coming 30 days — things are somewhat murky. What the executive order did say, though, was an expedited hearing, meaning inside 30 days. So when the June 29 process gets going, they anticipate finishing it within 30 days, and if you compare that with what existed during the Biden administration, it's very different. So I believe there will be a definitive answer on how cannabis gets treated in every category, medical and adult use included, when that hearing ends. So as you might guess, we're quite enthusiastic about where this is headed. Previously we've discussed rescheduling and what we believe it will mean for the industry and for our operators. And I'd say we're delighted it's moving on this expedited time line. And I believe we will definitely see more capital reaching these operators' bottom line. And we've held discussions, and we do anticipate far greater appetite for growth once the 280E tax issue gets settled and operators know clearly which direction to take, and we expect that to occur fairly soon. Yet we believe that money will go toward expansion and that they'll turn to us for that expansion, in our view. Naturally, we also notice additional benefits from rescheduling. We believe there are particular states that have perhaps been somewhat undecided about a medical program or about switching medical over to adult use. We believe this rescheduling will genuinely assist those states in moving toward new programs; and finally, I'd say rescheduling is great for R&D — plenty of companies will be extremely keen to test a plant and enter into especially medical applications for the plant. So we're delighted by these developments and the expedited time line.
Paul, I'd like to pick up right where that questioning left off. When we examine this, the current situation is somewhat puzzling, since you have a war on drugs happening alongside promotion of medical usage. So what actually took place was that medical usage got moved down to Schedule III, while adult usage remains at Schedule I. Is that accurate? Or what precisely is the status right now? We all understand where this ultimately leads, and you can see where the path finishes. But what is the technical standing as of today?
As of today — and acting Attorney General Blanche is quite explicit, Alex, about the present situation — operators with licensed medical use enjoy the advantage of Schedule III. That represents 100% medical licenses. And as you're aware, every one of our operators holds medical licenses. So that covers 100% of the operators in our portfolio. I believe it's also evident from the choice they made concerning other use cannabis: they placed it on an expedited schedule beginning June 29, with resolution required inside 30 days. Therefore we aren't anticipating any drawn-out stretch similar to what occurred previously. So I'd say it's quite clear regarding the bifurcation decision, and that's acceptable. But meanwhile, the position we're in today is excellent, since it's 100% covering our medical license holders, and that's within our portfolio.
Alright, regarding that 280E exemption — since all your renters qualify as medical, which is how I grasped it, that's positive. But when it comes to 280E, do those very tenants obtain the complete deduction via their operating companies? Or does the IRS in some way separate their sales?
Well, what the DOJ order put forward was tax relief with retroactive application, open to every qualifying medical operator. So it ought to be 100% for medical operators. And like I said, that's the makeup of our portfolio. My guess is we'll see, via Treasury — and the order likewise asks Treasury to deliver an opinion sooner rather than later concerning what the retroactive impact of 280E will be for medical as well as adult use; however, over the near term, it's plain: 280E relief, 100% for holders of medical licenses.
Alright, so at the end of the day, whether they move product or not doesn't really change things — they're in the medical space, and later we'll learn what the lookback period on this actually is. From where you sit — and then when you folks review your credit, when your tenants have run into credit trouble, and we're talking about several years out from now, I mean, it just keeps going — do you believe that as soon as the 280E relief lands, that essentially wipes away any credit problems still coming down the pike? Or do you think we'll still see the possibility of credit issues even with that 280E relief in place? I suppose that's — as you're aware, that's the thing we've been zeroed in on, this endless game of whack-a-mole, and it would be wonderful to get beyond it and see everybody standing on firmer ground. But I'm just wondering whether the 280E relief by itself, together with the retroactivity, more or less takes care of it? Or whether those credit troubles will persist simply because the tenants — the ones dealing with problems or debt refinancing, whatever it may be, still face that, and 280E won't truly do much to fix that side of things.
Alex, every business operates the same way. Risk exists everywhere. Every one of them has — every sector has tenants that — or companies that expand, contract, vanish; what 280E does is give these businesses improved operating conditions and improved operating metrics, yet they remain businesses. And all of them go through — all of them have solid management, okay, management that must redirect its attention to the business. So we'll encounter what every industry encounters, exactly like any other real estate firm out there leasing space to any kind of business.
All right, and one last thing. You brought up IQHQ and additional life science efforts, which your deck showed. Alan, when you take a look at the business over what we'll say is the coming 5 years, would you describe the life science share as closer to 50 to 50 or 25 to 75? Or I'm simply attempting to figure out whether life science will move toward 50% or remain a tiny piece of the company across the next, let's say, 5 years. And I won't pin you down on it. It's only about getting a sense of where you believe the strongest investment opportunity lies in the years ahead.
That's an extremely hard thing to respond to. What I can tell you, though, is that at present we find ourselves with a cannabis sector that is gaining strength. And when you look at how much is happening within life science, we — I believe our point of entry came during one of the weakest stretches that industry has seen in quite a while. And a life science sector that is rebounding strongly is what we're witnessing. So we've put ourselves in a position to seize opportunities aggressively through 2 industries, in my view, that are expanding and will assist us in generating growth for our shareholders going forward.
To build a bit on what was just asked, I want to focus more narrowly on IQHQ and the additional investments. From what I read in the filings, you mentioned starting additional investments in 2Q '26. I just want to confirm — is that still the plan? And could you perhaps provide a bit more detail regarding those additional investments in IQHQ preferred stocks and when they might occur over the near to medium term.
Yes. I think we've laid out the investment in the IQHQ organization all the way through 2027, mid-2027; and because these are highly accretive transactions, we've managed to pull forward a few of those planned investments to our advantage. As you may remember, it's north of 14% on average, and our cost of capital tied to our credit facility for making those investments sits in the 6% range; so these are extremely accretive investments, and we've been able to accelerate some of that. Our view remains that the life science industry, which IQHQ operates within, is performing really well. And we believe our investments will — we will keep evaluating opportunities to make investments at the right moment.
Alright, thanks a lot for those details. My next question is about cannabis. It's encouraging to see the headway you're making with fresh leases for tenants that had previously defaulted. When we consider how Schedule III opens up additional possibilities for you, could you discuss some of the opportunities in the near to somewhat medium term? You appear to have referenced your capacity to become more aggressive with acquisitions, adding more net new tenants. In the near term, where do you expect those to come from — would it be exclusively medical, given the certainty that exists there, and perhaps states such as Texas, Kentucky, or Georgia? Just offer us additional detail and granularity regarding where you foresee potential opportunities in the near term, in places where we only have clarity on medical, versus the longer-term opportunities while we await the second phase of rescheduling.
Thanks for asking that. We are — we're evaluating every acquisition possibility and for expansion during the latter half of 2026 and definitely going into 2027. However, our top priority and focus at this moment is ensuring we finish the refinancing of our unsecured debt, which we've completed — the team has achieved enormous success, and we have strong confidence. And after we finish that and fulfill our commitment to IQHQ, I believe we can then consider further opportunities moving forward.
I'd like to continue on the topic of rescheduling and get a sense of whether you believe interstate commerce could emerge as a result of it. If that were to happen, would you view your cultivation assets as an opportunity in such a scenario? Or might there be a risk involved? How would you go about preparing for that possibility?
Bill, this is Paul. I think you've raised 2 questions there. Let me take the first one — the answer is no, rescheduling does not deal with interstate commerce. Nor does it deal with banking. Those are 2 areas some folks hoped would get some clarity, and the Attorney General made it clear that interstate commerce, banking, and uplisting were matters not covered in this piece. As for your follow-up on interstate commerce, that's really something, I believe, we've discussed over the years. We don't see it occurring until cannabis is fully legalized across the board. And in our view, that's many years away. Yet, as we've talked about previously, even if some form of interstate commerce comes about, we believe our assets and our operators will perform well, since what we have is mostly indoor cultivation and medical, highly specialized product. That's likely not what will be moving on trucks across the country. So even in an interstate commerce situation, we think we're well positioned. But once again, we don't see that for many years.
All right. Then there's a potential demand catalyst that could help your tenants in November, unless something shifts regarding intoxicating hemp on a federal level — a ban. My guess is that not many of your properties are cultivating much of that. So I'd like to hear your view on what the disappearance of intoxicating hemp might mean for your tenants and for demand for the products they cultivate.
Yes. I believe that's right, Bill — our tenants aren't hemp farmers; they grow cannabis; and we've been monitoring how the entire litigation matter around hemp is really just sort of a sideshow, in the sense that we don't think hemp, either way, will truly impact our operators' business. That said, I think a prohibition on intoxicating hemp products would bring some clarity to this matter, and it would eliminate some of the Delta 8 stores that we see appearing in nonmedical states. So I think it's beneficial for the cannabis industry to obtain clarity in the intoxicating hemp legislation.
Appreciate it, and I want to thank everyone for being here today. I definitely want to express gratitude to the team for everything they've put in — really outstanding effort — and to our stockholders for sticking with us; that wraps up this call.
That wraps up today's session, everyone. We appreciate each of you for being here. You're free to end the connection at this point.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete Innovative Industrial Properties, Inc. transcript - plus 132,000+ transcripts from 7,000+ companies, speaker segments and full-text search - through the EarningsAPI REST API or hosted MCP server.
Get an API key View API docs →For developers and AI pipelines
Programmatic access to Innovative Industrial Properties, Inc. earnings transcripts and 132,000+ others is available through the
EarningsAPI REST API and the hosted MCP server.
Quarterly plans from $162 - full transcripts, speaker segments, full-text search,
and the /api/v1/transcripts/recent polling endpoint for ETL pipelines.